

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. *N Engl J Med* 2015;373:737-46. DOI: 10.1056/NEJMoa1503747

Supplementary Material

Table of Contents

Appendix 1 - Figure S1: Consort Diagram	2
Appendix 2 - Figure S2A: Time to Castration Resistant Prostate Cancer	3
Appendix 3 - Figure S2B: Time to Clinical Progression	4
Appendix 4 - Table S1: Causes of Death	5
Appendix 5 - Table S2: Docetaxel doses given	6
Appendix 6 - Table S3 Therapy beyond confirmed progression	7

Figure S1: CONSORT Diagram




Figure S2A: Time to Castration Resistant Prostate Cancer





Figure Legend: Time to castration resistant prostate cancer: time from randomization to PSA progression or clinical progression, whichever occurs first. Patients without documented progression of any kind were censored at the date of last disease assessment.

Figure S2B: Time to Clinical Progression



Number at Risk								
ADT+D	397	279	151	75	38	6	1	0
ADT alone	393	235	110	54	18	3	1	0

Figure Legend: Time to clinical progression was defined as the time from randomization to clinical progression. Patients without clinical progression were censored at the date of last clinical disease evaluation

Table S1: Causes of Death

	ADT + D (N=397)		ADT alone (N=393)	
	N	%	N	%
Due to prostate cancer	85	84.2	114	85.1
Due to protocol Rx	1	1.0	0	0.0
Other cause	8	7.9	11	8.2
Unknown	7	6.9	9	6.7
Missing	0		2	
Total	101		136	

Table S2: Docetaxel doses given

	ADT + Docetaxel (N=390*)	
Number of cycles	Patients	%
1	12	3.1
2	7	1.8
3	7	1.8
4	13	3.3
5	15	3.9
6	335	86.1
Unknown	1	
Total treated patients	390	

***Among 390 treated patients.**

Table S3: Therapy beyond confirmed progression

	ADT + D (N=397) N	ADT (N=393) N
Serological progression/ clinical progression	238	287
Clinical progression	180	228
Docetaxel[°]		
	54	137[^]
Other chemotherapy		
Cabazitaxel[°]	57	37
Mitoxantrone and/or platinum	29	27
Hormonal therapy		
Abiraterone and/or enzalutamide[°]	105[*]	104[#]
Antiandrogen and/or ketoconazole	80	91
Immunotherapy		
Sipuleucel T[°]	22	19
Radiotherapy	69	79
Use of agent(s) shown to prolong overall survival for mCRPC		
1 or more	150	187
2 or more	71	83

This data set represents number of patients who had progressed and treatment given as of December 23, 2014 whereas survival data represents data as of December 23, 2013.

[^]10 other patients had docetaxel prior to confirmed progression.

^{*}2 pts may have had placebo on trial

[°] Denotes agents with phase 3 data noted to prolong overall survival in metastatic CRPC (mCRPC)

[#]9 pts may have had placebo on trial